KCL-286 acts as a retinoic acid receptor-beta (RARβ) agonist, modulating Vitamin A pathways to influence gene regulation. By activating this system, the small molecule facilitates the repair of DNA double-strand breaks—a severe form of genetic damage—while simultaneously suppressing inflammatory responses that contribute to neuron loss early in the disease progression.